Group B Streptococcus Vaccines: Progress and Potential

키워드

참고문헌 (48)

1. Kong F, "Serotype identification of group B streptococci by PCR and sequencing", J Clin Microbiol, 40, pp.216~226 (2002)
2. Hanna M, "StatPearls" (2020), StatPearls Publishing
3. Russell NJ, "Maternal colonization with group B Streptococcus and serotype distribution worldwide : systematic review and meta-analyses", Clin Infect Dis, 65, pp.S100~S111 (2017)
4. Blencowe H, "National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000 : a systematic analysis", Lancet Glob Health, 4, pp.e98~e108 (2016)
5. Lawn JE, "Every newborn: progress, priorities, and potential beyond survival", Lancet, 384, pp.189~205 (2014)
6. Liu L, "Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis", Lancet, 385, pp.430~440 (2015)
7. Seale AC, "Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children", Clin Infect Dis, 65, pp.S200~S219 (2017)
8. "Group B Strep (GBS)"[URL]
9. Braye K, "Group B streptococcal screening, intrapartum antibiotic prophylaxis, and neonatal early-onset infection rates in an Australian local health district : 2006-2016", PLoS One, 14, pp.e0214295~ (2019)
10. Horsley L, "CDC updates guidelines for the prevention of perinatal GBS disease", Am Fam Physician, 83, pp.1106~1110 (2011)
11. Fairlie T, "Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease", Obstet Gynecol, 121, pp.570~577 (2013)
12. Pintye J, "Risk factors for late-onset group B streptococcal disease before and after implementation of universal screening and intrapartum antibiotic prophylaxis", J Pediatric Infect Dis Soc, 5, pp.431~438 (2016)
13. Carreras-Abad C, "A vaccine against group B Streptococcus : recent advances", Infect Drug Resist, pp.1263~1272 (2020)
14. Nogacka A, "Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates", Microbiome, 5, pp.1~10 (2017)
15. Azad MB, "Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study", BJOG: Int J Obstet Gynaecol, 123, pp.983~993 (2016)
16. Corvaglia L, "Influence of intrapartum antibiotic prophylaxis for group B Streptococcus on gut microbiota in the first month of life", J Pediatr Gastroenterol Nutr, 62, pp.304~308 (2016)
17. "Serotypes and the importance of serotyping Salmonella"[URL]
18. Madrid L, "Infant group B streptococcal disease incidence and serotypes worldwide : systematic review and metaanalyses", Clin Infect Dis, 65, pp.S160~S172 (2017)
19. Kang HM, "Genotype characterization of group B Streptococcus isolated from infants with invasive diseases in South Korea", Pediatr Infect Dis J, 36, pp.e242~e247 (2017)
20. Yao Z, "Identification of group B Streptococcus serotypes and genotypes in late pregnant women and neonates that are associated with neonatal early-onset infection in a South China population", Front Pediatr, 8, pp.265~ (2020)
21. Hannoun A, "Correlation between group B streptococcal genotypes, their antimicrobial resistance profiles, and virulence genes among pregnant women in Lebanon", Int J Microbiol, 2009 (2009)
22. Takashi Takahashi, "Clonal Distribution of Clindamycin-Resistant Erythromycin-Susceptible (CRES) <italic>Streptococcus agalactiae<", italic> in Korea Based on Whole Genome Sequences, 2020, pp.40(5), 370~381[DOI]
23. Udo EE, "Genotypes and virulence genes in group B Streptococcus isolated in the maternity hospital, Kuwait", Med Princ Pract, 22, pp.453~457 (2013)
24. Zakerifar M, "Antibiotic resistance genes and molecular typing of Streptococcus agalactiae isolated from pregnant women", BMC Pregnancy Childbirth, 23, pp.1~13 (2023)
25. Berner R, "Group B Streptococcus vaccines: one step further", Lancet Infect Dis, 21, pp.158~160 (2021)
26. "Routine vaccines, extraordinary impact: Group B Streptococcus (GBS)"[URL]
27. Baker CJ, "Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection", N Engl J Med, 294, pp.753~756 (1976)
28. Lin FYC, "Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study", J Infect Dis, 184, pp.1022~1028 (2001)
29. Baker CJ, "Maternal antibody at delivery protects neonates from early-onset group B streptococcal disease", J Infect Dis, 209, pp.781~788 (2014)
30. Johri AK, "Group B Streptococcus : global incidence and vaccine development", Nat Rev Microbiol, 4, pp.932~942 (2006)
31. Paoletti LC, "Conjugate vaccines against group B Streptococcus types IV and VII", J Infect Dis, 186, pp.123~126 (2002)
32. Wessels M, "Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus", J Clin Invest, 86, pp.1428~1433 (1990)
33. Kasper DL, "Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine", J Clin Invest, 98, pp.2308~2314 (1996)
34. Baker CJ, "Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III", J Infect Dis, 188, pp.66~73 (2003)
35. Ali MM, "Group B Streptococcus colonization rate and serotype distribution among pregnant women and their newborns at Adama Hospital Medical College", Ethiopia. Sci Rep, 10, pp.9301~ (2020)
36. Baker C, "Group B streptococcal conjugate vaccines", Arch Dis Child, 88, pp.375~378 (2003)
37. Dhar N, "Immune responses against group B Streptococcus monovalent and pentavalent capsular polysaccharide tetanus toxoid conjugate vaccines in Balb", c mice, 2023, pp.26, 107380~
38. Dominguez K, "Toward the development of a protein-based group B Streptococcus vaccine", Cell Rep Med, 3, pp.100536~ (2022)
39. Fischer P, "Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine(GBS-NN)against Group B Streptococcus in a randomized placebo-controlled double-blind phase 1 trial in healthy adult women", Vaccine, 39, pp.4489~4499 (2021)
40. Pawlowski A, "A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains", Cell Rep Med, 3, pp.100511~ (2022)
41. "Group B streptococcal infections: the Division of Bacterial and Mycotic Diseases National Center for Infectious Diseases Centers for Disease Control and Prevention"[URL]
42. "MinervaX commences first phase 1 clinical study of novel GBS vaccine in older adults"[URL]
43. McLaughlin JM, "The burden of adults hospitalized with group B streptococcal infection", J Infect Dis, 224, pp.1170~1178 (2021)
44. "Active bacterial core surveillance report, emerging infections program network, group B Streptococcus" (2009)[URL]
45. Smith E, "Group B Streptococcus infections of soft tissue and bone in California adults, 1995–2012", Epidemiol Infect, 143, pp.3343~3350 (2015)
46. Lamagni TL, "Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010", Clin Infect Dis, 57, pp.682~688 (2013)
47. Palazzi DL, "Use of type V group B streptococcal conjugate vaccine in adults 65–85 years old", J Infect Dis, 190, pp.558~564 (2004)
48. "MinervaX initiates Phase I GBS vaccine trial in older people"[URL]

관련 논문AI추천